Biotechs Target Stagnant Baldness Market

    February 2016 in “ Nature Biotechnology ”
    C. D. Schmidt
    Image of study
    TLDR New drug shows promise for better hair growth in baldness treatment.
    In 2016, Samumed reported positive phase 2 trial results for SM04554, a drug aimed at treating male-pattern baldness, with 300 participants showing increased hair density and improved hair quality without serious side effects. This marked a potential breakthrough in a market dominated by limited options like Propecia and Rogaine, which only slow hair loss. Samumed's drug, which stimulates hair growth by upregulating WNT activity, differs from traditional treatments that focus on anti-androgen effects. Other companies, such as Allergan, were also developing new therapies, though experts warned that a complete cure for baldness was unlikely and effectiveness would vary among individuals.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 9 results

      community Is Breezula The Real Deal?

      in Question  16 upvotes 6 years ago
      The conversation is about the effectiveness of Breezula for hair loss, with skepticism expressed due to lack of scientific proof and mixed results from those using Breezula and RU58841. Some are waiting for clinical trial results before trying treatments like Breezula and SM04554.

      community Anyone here holding out for Breezula?

      in Treatment  7 upvotes 5 years ago
      The conversation is about individuals considering waiting for Breezula to treat hair loss instead of using Finasteride due to concerns about side effects. Some are opting for Finasteride now, while others are wary of its impact on neurosteroids.

    Related Research

    5 / 5 results